At the time of writing, Takeda Pharmaceutical Co ADR [TAK] stock is trading at $14.84, up 2.98%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TAK shares have gain 5.40% over the last week, with a monthly amount glided 8.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on March 16, 2023, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, Cowen upgraded its rating to Outperform on July 19, 2022, and elevated its price target to $24. On October 07, 2021, downgrade downgraded it’s rating to Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen initiated its recommendation with a Market Perform and recommended $19.50 as its price target on November 01, 2019. Daiwa Securities downgraded its rating to Neutral for this stock on August 15, 2019.
For the past year, the stock price of Takeda Pharmaceutical Co ADR fluctuated between $12.57 and $15.08. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $14.84 at the most recent close of the market.
Analyzing the TAK fundamentals
According to Takeda Pharmaceutical Co ADR [NYSE:TAK], the company’s sales were 30.22B for trailing twelve months, which represents an -0.06% plunge. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.03 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.58 points at the first support level, and at 14.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.08, and for the 2nd resistance point, it is at 15.31.
Ratios To Look Out For
It is important to note that Takeda Pharmaceutical Co ADR [NYSE:TAK] has a current ratio of 1.31. In addition, the Quick Ratio stands at 0.72 and the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 1.56, the price to book ratio is 1.00 and price to earnings (TTM) ratio is 34.90.
Transactions by insiders
Recent insider trading involved Giles Richard Platford, President, Plasma-Derived Ther, that happened on Aug 23 ’24 when 19073.0 shares were purchased.
